Sleepio is a revolutionary digital treatment for insomnia

Helping people overcome their insomnia for good with care that’s available anytime, anywhere.

Request Demo

In a clinical trial, 76% of patients experienced clinically significant improvement in insomnia


reduction in time to fall asleep.1


less time awake at night.1


better functioning the next day.1

For the past decade, we’ve been putting Sleepio to the test in gold-standard clinical trials.

Sleepio use was shown to lower health care costs by $1,677 per employee*

A health economic evaluation with IBM Watson Health and a Fortune 500 employer demonstrated that Sleepio generated a significant per-employee health care cost reduction.2

Sleepio delivers meaningful, lasting results

Sleepio addresses unique needs with a customized program featuring sessions with step-by-step guidance through evidence-based techniques. In about 20 minutes per week, individuals can quiet their racing minds, reshape behaviors, and get better sleep.

Customized therapeutic content

Sleepio adjusts therapeutic content to each individual’s needs and offers additional tools and insights when needed.

Help at any time, day or night

When it’s needed the most, Sleepio is instantly accessible and ready to check in, practice, or try a new technique.

Progress tracking

Sleepio provides customized goal setting, a detailed sleep diary, and helps track progress over time.

What Sleepio users say

Sleepio has made a huge change in my ability to fall asleep quickly and have restful sleep.

Sleepio User

September, 2020

I’ve had insomnia for 18 years. Sleepio has brought my average sleep from two hours a night to seven hours a night.

Member in UK

October, 2020

I can’t believe I learned so much in such a short time after suffering for decades. This program is brilliant.

Member in US

April, 2021

During the COVID-19 public health emergency, Sleepio is temporarily being made available as a treatment for insomnia disorder without a prescription. Sleepio has not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

1. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.
2. Miller, C. B., Carl, J. R., Henry, A. L., Baker, L. (2020). A health economic evaluation of Sleepio at a Fortune 500 company. Retrieved from: *This is a total estimate that is based on statistically significant and non-significant reductions in costs across categories; thus the exact figure would require confirmation in further research with a larger sample size.3. CDC – Data and Statistics – Sleep and Sleep Disorders. (2017). CDC.
4. Varkevisser, M., & Kerkhof, G. A. (2005). Chronic insomnia and performance in a 24‐h constant routine study. Journal of Sleep Research, 14(1), 49-59.
5. Shahly, V., Berglund, P. A., Coulouvrat, C., Fitzgerald, T., Hajak, G., Roth, T., … & Kessler, R. C. (2012). The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Archives of general psychiatry, 69(10), 1054-1063.
6. Hertenstein, E., Feige, B., Gmeiner, T., Kienzler, C., Spiegelhalder, K., Johann, A., … & Baglioni, C. (2019). Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep medicine reviews, 43, 96-105.
7. Sanofi-Aventis U.S. LLC. (2008). Ambien prescribing information: NDA 19908 S027 FDA approved labeling 4.23.08. Retrieved Jul 25, 2023, from
8. Sunovion Pharmaceuticals Inc. (2014). Lunesta prescribing information. Retrieved Jul 25, 2023, from

DOC-3043 Effective 07/2023